Het Van Weel-Bethesda Ziekenhuis
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department focuses on cardiovascular disease prevention and treatment, targeting patients at high risk of heart events and those with heart failure phenotypes.
- Investigating novel lipid‑lowering therapies to reduce heart attacks and strokes
- Assessing anti‑inflammatory agents for major adverse cardiovascular events
- Exploring treatments that combine weight loss with cardiovascular protection
- Studying outcomes of new heart‑failure drugs in obese patients
Het Van Weel‑Bethesda Ziekenhuis collaborates with regional cardiology networks to advance these studies.
Neoplasms
Research in this area addresses cancer across several tumor types, from breast and triple‑negative disease to lung and multiple myeloma.
- Testing de‑escalated chemotherapy combined with HER2‑targeted therapy
- Comparing continuous versus intermittent antibody‑drug regimens in multiple myeloma
- Evaluating immunotherapy addition to adjuvant treatment for early‑stage triple‑negative breast cancer
- Assessing shortened chemo‑immunotherapy schedules for metastatic non‑small cell lung cancer
The site’s oncology unit integrates trial data with national cancer registries to improve patient outcomes.
Hormonal Diseases
The cardiology department also conducts studies on hormonal disorders, particularly thyroid dysfunction and its impact on quality of life.
- Comparing combination levothyroxine/liothyronine therapy to standard levothyroxine alone
- Investigating genetic markers that influence response to thyroid hormone replacement
Findings aim to personalize treatment for patients with persistent fatigue despite conventional therapy.
Nervous System Diseases
Studies target neurological conditions such as chronic subdural hematoma, evaluating less invasive management strategies.
- Testing tranexamic acid to reduce the need for surgical evacuation
- Monitoring functional recovery and re‑bleeding rates with conservative care
The hospital’s neurosurgery team works closely with cardiology to ensure comprehensive patient monitoring.
Nutritional and Metabolic Diseases
The site addresses metabolic health, focusing on obesity, type 2 diabetes, and severe hypertriglyceridemia.
- Evaluating a new weekly peptide that may lower major cardiovascular events in diabetic patients
- Testing an oral agent aimed at reducing cardiovascular risk in atherosclerotic disease and chronic kidney disease
- Assessing an antisense drug for severe hypertriglyceridemia to improve lipid profiles
Collaborative efforts with dietitians and endocrinologists support the holistic management of metabolic risk.
Bacterial Infections and Mycoses
Research includes acute infectious conditions, notably sepsis, to refine critical‑care interventions.
- Comparing a novel dosing protocol to standard care for sepsis patients in intensive care
- Measuring short‑term survival and organ‑function recovery under the new regimen
The hospital’s intensive‑care unit integrates these trials with real‑time monitoring systems.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 52 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 50 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ionis Pharmaceuticals Inc.3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Het Van Weel-Bethesda Ziekenhuis
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 52 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 3 | Unknown | 2023-05-17 | 2023-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.